Safety and Efficacy of KL003 Cell Injection in Severe Sickle Cell Disease

NCT07436767 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

3

Enrollment

OTHER

Sponsor class

Conditions

Sickle Cell Disease

Interventions

GENETIC: KL003 Cell Injection

Sponsor

Institute of Hematology & Blood Diseases Hospital, China